Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transvaginal Mesh Devices Reassessed: FDA Panel Set For September

This article was originally published in The Gray Sheet

Executive Summary

Industry, physicians and FDA are all prepping for what is likely to be a major meeting in the lifecycle of transvaginal surgical mesh devices early next month.
Advertisement

Related Content

FDA Proposes PMAs For Pelvic Organ Prolapse Mesh Devices
Surgical Mesh And Sling Devices Must Undergo Post-Market Studies
FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III
FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III
Regulatory News In Brief
Regulatory News In Brief
Regulatory News In Brief
Regulatory News In Brief
Research In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT030469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel